# TB-500 Prescribed

> A curated reading of the Thymosin Beta-4 record — what the prescription question actually answers to.

## Pages

- [TB-500 Prescribed — Is TB-500 a prescription drug? A wall-label reading of the evidence](/index.md): TB-500 is a synthetic 7-amino-acid fragment of Thymosin Beta-4. It is not FDA-approved, not eligible for compounding, and not prescribable. A curated reading of the actual research record.
- [TB-500 reported effects and safety — what the community says and what the research cautions](/effects.md): TB-500 reported effects, real-world community signals, and safety cautions drawn from published research — anecdotal, not clinical evidence.
- [TB-500 / Thymosin Beta-4 research record](/research.md): A reading of the Thymosin Beta-4 literature from 1992 to 2025: actin sequestration, dermal and corneal healing, cardiac repair, Phase I-III human trials, and recent hydrogel work.
- [TB-500 / Thymosin Beta-4 dosing in the published research](/dosage.md): A research-context summary of the doses and routes used in published Thymosin Beta-4 studies. No clinical dosing protocol exists for the synthetic TB-500 fragment.
- [TB-500 frequently asked questions](/faq.md): Direct answers to the questions readers arrive with: prescription status, FDA approval, compounding, the fragment-versus-parent distinction, WADA status, and legality.
- [References — TB-500 / Thymosin Beta-4](/references.md): Full citation list for the TB-500 / Thymosin Beta-4 record, with DOIs and PubMed or PMC links. Twenty-seven peer-reviewed and regulatory primary sources.
- [About — TB-500 Prescribed](/about.md): TB-500 Prescribed is an independent editorial reading room that summarizes the peer-reviewed Thymosin Beta-4 research literature. Not a clinic, not a pharmacy.
- [Contact — TB-500 Prescribed](/contact.md): Contact the editors of TB-500 Prescribed. Editorial corrections, source suggestions, and reference updates welcome. Not a clinical service.